Bayesian Capital Management LP Buys New Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

Bayesian Capital Management LP bought a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,029 shares of the company’s stock, valued at approximately $267,000.

A number of other large investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its stake in Keros Therapeutics by 356.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,460 shares of the company’s stock worth $138,000 after acquiring an additional 2,702 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after acquiring an additional 324 shares in the last quarter. Arizona State Retirement System acquired a new position in Keros Therapeutics during the fourth quarter worth $231,000. CANADA LIFE ASSURANCE Co raised its stake in Keros Therapeutics by 117.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 5,217 shares of the company’s stock worth $345,000 after acquiring an additional 2,822 shares in the last quarter. Finally, Perpetual Ltd acquired a new position in Keros Therapeutics during the first quarter worth $443,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

KROS has been the subject of several recent analyst reports. Truist Financial reiterated a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Oppenheimer began coverage on Keros Therapeutics in a report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $92.17.

Keros Therapeutics Stock Performance

Shares of KROS stock opened at $50.16 on Thursday. The stock’s fifty day moving average is $47.34 and its 200-day moving average is $55.41. The stock has a market capitalization of $1.81 billion, a PE ratio of -9.74 and a beta of 1.23. Keros Therapeutics, Inc. has a 52 week low of $27.02 and a 52 week high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($1.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.33) by $0.12. The firm had revenue of $0.08 million during the quarter. The firm’s revenue was down 97.3% compared to the same quarter last year. During the same quarter last year, the company posted ($1.26) EPS. As a group, analysts forecast that Keros Therapeutics, Inc. will post -4.8 earnings per share for the current fiscal year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.